other material
confidence high
sentiment neutral
materiality 0.60
Silo Pharma shareholders approve 1:2-1:20 reverse split and increase equity plan shares to 1.4M
Silo Pharma, Inc.
- Reverse split authorized at ratio from 1-for-2 to 1-for-20, board may implement before October 24, 2026.
- Omnibus equity plan share reserve raised from 470,000 to 1,400,000 shares, plus automatic annual increase.
- All four director nominees re-elected; ratification of Salberg & Company as auditor approved.
- Reverse split proposal received 3,896,499 for vs 1,253,332 against; plan amendment got 1,343,678 for vs 514,675 against.